If you have been reading about Thymosin alpha 1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
== Advantages and disadvantages == This laboratory technique has various advantages. First, these tests are relatively cheap, relatively straightforward and allow for real-time measurements. Additionally, the testing conditions can be easily adjusted to fit different experimental objectives. This approach also allows for a strong directional migratory response making quantifying data simple. One limitation of this assay is that there could be inconsistencies with the depth and size of the scratch. When the scratch is done manually, it's susceptible to 'ragged' edge boundaries, which make analyzing data more difficult. Also, the damage could physically damage the cells adjacent to the wound and create inaccurate wound size areas. This limitation is slowly becoming less of an issue with automated technologies. The Electric Cell Impendance Sensing assays utilize to prevent damage to the cells in the underlying extracellular matrix that can likely happen with the manual scratching approaches. Additionally, the Woundmaker makes fast and uniform wounds across various numbered well-plates options (96 or 384) and allows for high throughput screening, which is a major advantage for various medical research studies. Despite the new technology that is increasing this assay's accuracy and efficacy, there are still confounding factors that can skew the assay results, such as cell "crowding", cell/cell adhesion effects and matrix effects. Additionally, there is still mention with the problem of accumulation of cells at the edge of the scratch, making the cell densities uneven.
== Therapeutic uses == Given that the endocannabinoid system maintains an internal balance in various body systems, cannabinoid receptor modulators, as compounds that interfere with the endocannabinoid system by interacting with its receptors, carry multiple therapeutic potentials. Cannabinoid receptor 1 (CBR1) are a potential target for treating pain and cognitive impairment. However, modulators of CBR1 (molecules that interact with CB1R) have limited medical use due to psychotropic side effects (e.g. depression and anxiety) associated with CB1R interference. As the activation of cannabinoid receptor 2 (CBR2) has no psychotropic effects, modulators of CB2R (molecules that interact with CB2R) are investigated for various therapeutic potentials. CB2 receptor agonist (molecules that stimulate the activity of the receptors) has been investigated as treatment for pain, inflammation, immune disorders and brain diseases, whereas CB2 inverse agonist or antagonist (molecules that inhibit the activity of the receptors) for weight loss, mental disorder and osteoporosis. Although the efficacy of cannabinoid receptor modulators is supported by preclinical evidence, only four cannabinoid receptor modulators are approved for therapeutic uses, with the rest under trials.
The award recognizes late career stage faculty with outstanding scientific achievement and a strong history of leadership in mentoring the careers of men and women in science. This award emphasizes leadership and support of marginalized groups.
==== Recent advances ==== Since the early 2000s, advances in droplet-based microfluidics have made it a powerful technique for conducting directed evolution campaigns. Early developments in bulk production of single-emulsions (SEs; e.g. "water-in-oil" droplets) and double-emulsions (DEs; e.g. "water-in-oil-in-water" droplets) were followed by innovations in on-chip formation and sorting of SEs and DEs, which allow for greater ease and throughput of directed evolution experiments on microfluidic chips. An essential component of directed evolution is the maintenance of the linkage between enzymatic genotypes and phenotypes. The ability to form DEs on-chip and subsequently sort using fluorescence-activated cell sorting (FACS) pushed the field forward. In 2013, Yan et al. showed the use of FACS to sort DEs. In 2014, Zinchenko et al. published a system to formulate monodisperse DEs and to sort and quantitatively analyze them using a commercially available flow cytometer. The authors demonstrated the power of their system by enriching an active wild-type arylsulfatase from populations of 0.1% and 0.01% active cells by 800- to 2500-fold, respectively. In 2016, Larsen et al. developed a fluorescence-based optical sorting system to monitor polymerases activity inside a microfluidic device. Using their system, Larsen and colleagues showed approximately 1200-fold enrichment of an engineered polymerase.
== Therapeutic uses == SAMe has been studied for depression, osteoarthritis, and liver diseases with inconclusive results, and while generally considered safe short-term, its long-term safety, use during pregnancy, and risks for people with bipolar disorder or compromised immune systems remain unclear.
Sources: en.wikipedia.org
=== Communist League === In 1958, the Provisional Organizing Committee to Reconstitute a Marxist–Leninist Party (POC) split from the Communist Party of the United States. In 1968, Nelson Peery and his wife, Sue Ying Peery, led a small group out of the POC and formed the California Communist League (CL).. In California, several Mexican American groupings joined the CL. A group of African American autoworkers in Michigan, from the League of Revolutionary Black Workers merged into the CL. The CL organized forums with different left groups and individuals to develop a new communist party. These forums were held in several cities around the United States . Due its policy of advancing into leadership women, national minorities and workers, the CL had a leadership grouping different from other groups on the left.
== Clinical significance == A change in the structure of a conjugated protein can change the function and result in a number of different diseases. For example, changes in the primary structure of hemoglobin causes sickle cell anaemia and thalassemia, both of which change the way oxygen is transported in the bloodstream. Moreover, lipoproteins' level abnormalities can cause or worsen atherosclerosis as the amounts of cholesterol increase in the artery walls. Glycoproteins can also be used as markers for certain diseases. Changes in glycosylation are associated with some cancers, inflammation, and autoimmune diseases. Anemia and Wilson's disease can also be caused by mutations in metalloproteins as they are responsible for transporting metal ions. In medicine, conjugated protein can be used in vaccines. For example, polysaccharide-protein conjugate vaccines can increase the effectiveness of vaccines.
=== APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia === The authors of this study sought to determine the effect on metabolism of the drug risperidone in schizophrenia patients. After discovering that risperidone did have negative metabolic side effects, they tested membrane proteins for glucose and lipid transport in control and experimental groups by MALDI-TOF and fingerprinting. Results showed altered fingerprints and therefore altered levels of folding in the proteins. So, they concluded that risperidone negatively effects glucose and lipid transport proteins in the cell membranes of patients.
Parasitic infestations, stings, and bites in humans are caused by several groups of organisms belonging to the following phyla: Annelida, Arthropoda, Bryozoa, Chordata, Cnidaria, Cyanobacteria, Echinodermata, Nemathelminthes, Platyhelminthes, and Protozoa.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.